Website
N/ATelephone
61.3.4331.9974
Address
Suite 2, Level 11 385 Bourke Street Melbourne, Victoria (VIC) 3000
Description
N/A
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 1.08 - 2.1
Trade Value (12mth)
AU$12,362.00
1 week
0%
1 month
6.67%
YTD
-8.57%
1 year
0%
All time high
2.10
EPS 3 yr Growth
N/A
EBITDA Margin
N/A
Operating Cashflow
N/A
Free Cash Flow Return
N/A
ROIC
N/A
Interest Coverage
N/A
Quick Ratio
N/A
Shares on Issue (Fully Dilluted)
N/A
HALO Sector
Healthcare
Next Company Report Date
11-Aug-26
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
AUD
Short Sell (% of issue)
0.00
Date | Announcements |
---|---|
05 August 25 |
FY25 Full Year Results Presentation - Amended
×
FY25 Full Year Results Presentation - Amended |
05 August 25 |
FY25 Corporate Governance Statement
×
FY25 Corporate Governance Statement |
05 August 25 |
FY25 Appendix 4G
×
FY25 Appendix 4G |
05 August 25 |
FY25 Full Year Results Presentation
×
FY25 Full Year Results Presentation |
05 August 25 |
FY25 Appendix 4E and Annual Report
×
FY25 Appendix 4E and Annual Report |
05 August 25 |
Leadership Transition at Vitrafy
×
Leadership Transition at Vitrafy |
31 July 25 |
Expiry of Voluntary Escrow Restrictions
×
Expiry of Voluntary Escrow Restrictions |
30 July 25 |
Q4 FY25 Quarterly Activities Report and Appendix 4C
×
Q4 FY25 Quarterly Activities Report and Appendix 4C |
29 July 25 |
Appendix 4C, FY25 Annual Results and Investor Call Schedule
×
Appendix 4C, FY25 Annual Results and Investor Call Schedule |
25 June 25 |
Notification of cessation of securities - VFY
×
Notification of cessation of securities - VFY |
30 May 25 |
Change of Address
×
Change of Address |
15 May 25 |
Application for quotation of securities - VFY
×
Application for quotation of securities - VFY |
02 May 25 |
Vitrafy Q3 FY25 Investor Presentation
×
Vitrafy Q3 FY25 Investor Presentation |
02 May 25 |
Release of Securities from Mandatory Escrow
×
Release of Securities from Mandatory Escrow |
29 April 25 |
Q3 FY25 Quarterly Activities Report and Appendix 4C
×
Q3 FY25 Quarterly Activities Report and Appendix 4C |
28 April 25 |
Vitrafy Q3 FY25 Investor Briefing
×
Vitrafy Q3 FY25 Investor Briefing |
16 April 25 |
USAISR successful Phase 1 Blood Platelet study
×
USAISR successful Phase 1 Blood Platelet study |
15 April 25 |
Notification regarding unquoted securities - VFY
×
Notification regarding unquoted securities - VFY |
08 April 25 |
Application for quotation of securities - VFY
×
Application for quotation of securities - VFY |
27 March 25 |
Release of Securities from Mandatory Escrow
×
Release of Securities from Mandatory Escrow |
20 March 25 |
NWR Virtual Healthcare Conference Presentation
×
NWR Virtual Healthcare Conference Presentation |
19 March 25 |
Vitrafy to present at NWR Virtual Healthcare Conference
×
Vitrafy to present at NWR Virtual Healthcare Conference |
19 March 25 |
Change of Director's Interest Notice
×
Change of Director's Interest Notice |
18 March 25 |
Vitrafy Awarded Industry Growth Program Grant
×
Vitrafy Awarded Industry Growth Program Grant |
28 February 25 |
Notification of cessation of securities - VFY
×
Notification of cessation of securities - VFY |
Load More
Load Less
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.